Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 program for...

Related Keywords

Tennessee ,United States ,Boston ,Massachusetts ,Marcio Souza ,Albertoj Espay ,Linkedin ,Grossman School Of Medicine ,Rogcon Inc ,Globenewswire Inc ,European Medicines Agency ,Praxis Precision Medicines Inc ,Drug Administration ,Exchange Commission ,Joana Gardner Center ,Epilepsy Study Consortium ,University Of Cincinnati ,Ionis Pharmaceutics Inc ,Nasdaq ,Facebook ,Precision Medicines ,Endowed Chair ,Daily Living ,New Drug Application ,Maximal Electroshock Seizure Model ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Medicines Agency ,Praxi Cerebrum ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Although Praxi ,Stone Evoke Canale ,Markets ,